RBFOX2 and hypoplastic left heart syndrome: De novo mutations of genes (TFE3, EDNRA, ZNF292, FOXM1, ZMYND19, PCBP3, TCF12, ARID1B, NOVA1, PKD1, RBFOX2, ST5, TSC1, USP8, HERC4, KMT2D, ETS1, CHD7, CTR9, GLA, FMNL1, PHRF1, SIPA1L1, and HIRA) predominantly manifest in the endocardium, coronary, and lymphatic ECs, providing a consolidated basis for targeting the endocardium in HLHS pathogenesis [8].